Nigeria has announced a target to produce cancer diagnostic and treatment equipment locally by 2030, with Minister of State for Health Dr. Tunji Salako leading the charge — a pledge that, if met, would mark a turning point for a country where most cancer patients still die before they receive a confirmed diagnosis.
An estimated 120,000 Nigerians are diagnosed with cancer each year, according to the Global Cancer Observatory, and the true figure is almost certainly higher given how rarely the disease is caught early. Breast, cervical, prostate, and colorectal cancers are the leading killers, with women in the South-West and South-South bearing a disproportionate burden of cervical and breast cancer deaths. For the overwhelming majority of patients outside Lagos, Abuja, and Port Harcourt, access to a functioning radiotherapy or imaging machine can mean a journey of hundreds of kilometres — assuming the machine at the nearest teaching hospital is not already out of service.
Nigeria has fewer than ten functional radiotherapy machines for a population of more than 220 million people. The World Health Organization recommends at least one unit per 500,000 people, which would put the country's minimum need at over 400 machines. The gap between that standard and reality is filled, overwhelmingly, by death — or by medical tourism that drains hundreds of millions of dollars annually to Ghana, India, and the United Kingdom, money that flows out of Nigerian households already strained by out-of-pocket health costs.
The 2030 local production target arrives within the broader framework of the federal government's push to reduce import dependency in the health sector, a policy pressure that intensified after the naira's sharp devaluation made foreign-sourced equipment dramatically more expensive for both government hospitals and private facilities. A radiotherapy linear accelerator that cost a Nigerian hospital ₦800 million in 2021 can now run to more than ₦2 billion at current exchange rates, pricing even well-resourced state governments out of the market.
Dr. Salako, speaking on the government's oncology roadmap, framed local manufacturing not merely as an economic ambition but as a survival imperative. The minister indicated that the government is working with research institutions, private sector partners, and international development agencies to build the technical and industrial capacity required to fabricate key components domestically — with the goal of reducing unit costs and eliminating the foreign exchange exposure that has long made oncology infrastructure a luxury rather than a baseline.
The timeline is tight and the obstacles are structural. Nigeria currently lacks the precision manufacturing base, the trained biomedical engineering workforce at scale, and the quality assurance infrastructure that local production of radiotherapy or advanced imaging equipment would demand. Watchers of the health sector will want to see concrete milestones — a funded prototype facility, signed industry partnerships, and a skills pipeline through institutions like the University of Lagos or Ahmadu Bello University — well before 2030 if the target is to be credible. The announcement also raises questions about the fate of Nigeria's National Cancer Control Plan, which has been underfunded since its last iteration, and whether state governments in Kano, Rivers, Enugu, and elsewhere will be brought into the manufacturing and deployment chain.
For the woman in Maiduguri or the man in Nnewi who will be diagnosed with cancer in 2029, the question is not whether Nigeria can build the machine — it is whether the machine will be there, switched on and staffed, by the time it is needed.
